Jeff Hall

"The reported bpMRI-based AI model detected the majority of locally recurrent prostate cancer after radiotherapy," the authors wrote in their study conclusion.

“Implementation of the most recent PI-RADS update did not improve the incongruence in prostate cancer grade assessment between MRI/ultrasound fusion targeted biopsy and surgery,” the authors wrote.

The incorporation of PSMA PET–imaging into a multivariate model enhanced the predictive accuracy for clinically significant prostate cancer in patients in the "PSA gray zone" of 4 to 10 ng/mL.

Use of non-contrast MRI also showed the potential to decrease identification of clinically insignificant disease.

A recent study suggests that combined use of ultrasound and multiparametric MRI-targeted biopsy with systematic biopsy may be more effective for detecting clinically significant prostate cancers than using systematic biopsies alone

Even in the era of PSMA-PET imaging, whole-body low-dose computed tomography still offers value in the management of patients with prostate cancer, according to a study published in Insights into Imaging.

“These findings suggest that the technical advantages of precision of radiotherapy delivery afforded by MRg-A-SBRT translate to measurable clinical benefit,” wrote lead study author Jonathan E. Leeman, MD.

Analysis shows MRI is comparable to post-surgery pathologic staging for assessing risk of biochemical recurrence.

The AI model was accurate and effective in an independent test set, according to the study authors.

Pelvic lymph node involvement and polymetastases detected with PSMA-PET imaging were linked to significantly lower overall survival rates in patients initially diagnosed with non-metastatic, castration-resistant prostate based on conventional imaging.

Researchers examined the impact of deep learning–based AI software upon radiologists reviewing multiparametric MRI scans in the assessment of clinically significant prostate cancer.

The deep learning software also showed no difference in the consistency of scoring with the Prostate Imaging-Reporting and Data System (PI-RADS).

“This study shows prostate artery embolization to be a safe and highly effective treatment whose long-term outcomes include sustained LUTS relief, significant improvement in quality of life and no change in erectile function,” according to Shivank Bhatia, MD.

“Vertebral fragility fractures are often asymptomatic and overlooked but are known to decrease quality of life, and can also affect mortality,” the authors wrote.

Using MRI-directed targeted biopsy instead of systematic biopsy for screening and early detection in patients with an elevated PSA lowered the risk of overdiagnosis by half.

“I think this trial will pave the way for patients with high-risk prostate cancer to be treated in 5 weeks instead of 8 weeks," said Tamim M. Niazi, MD.

The study authors maintain there is no current evidence in the literature indicating that CT use is superior to other imaging modalities in reducing morbidity or improving outcomes in patients with urinary stone disease.

Results from the phase 3 MIRAGE trial showed lower rates of genitourinary and gastrointestinal side effects with MRI guidance vs CT guidance when treating patients with stereotactic body radiotherapy.

A recent study suggests that radiomics analysis based on 68Ga-PSMA-11 PET may non-invasively predict intraprostatic lesions in patients with prostate cancer.

The FDA has granted 510(k) clearance to an artificial intelligence software program that may enhance the efficiency and accuracy of prostate cancer diagnosis.

The rate of positive surgical margins was higher among patients who did not have a preoperative MRI.

Micro-ultrasound yielded comparable detection rates for prostate cancer as multiparametric magnetic resonance imaging.